Methods of treating hypertriglyceridemia
View Patent ↗In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
1. A method of reducing triglycerides comprising, identifying a group of subjects having a median triglyceride level of at least 500 mg/dl and orally administering daily to at least one subject in the group of subjects a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters, by weight of all fatty acids, for a period of 12 weeks to reduce fasting triglycerides in the at least one subject.
2. The method of claim 1 , wherein the group of subjects has a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.
3. The method of claim 1 , wherein the group of subjects has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.
4. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce triglycerides by at least about 30% without increasing LDL-C in the at least one subject.
5. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce apolipoprotein B in the at least one subject.
6. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce VLDL-C in the at least one subject.
7. The method of claim 1 , wherein the group of subjects has a median fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.
8. The method of claim 1 , wherein the composition is present in one or more dosage units.
9. The method of claim 8 , wherein the dosage units are capsules.
10. A method of reducing triglycerides comprising, identifying a group of subjects having a median triglyceride level of at least 500 mg/dl and orally administering daily to at least one subject in the group four capsules per day, each capsule comprising about 900 mg to about 1 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters, by weight of all fatty acids, for a period of 12 weeks to reduce fasting triglycerides in the at least one subject.
11. The method of claim 10 , wherein the group of subjects has a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.
12. The method of claim 10 , wherein the group of subjects has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.
13. The method of claim 10 , wherein 12 weeks of said administering is effective to reduce triglycerides by at least about 30% without increasing LDL-C in the at least one subject.
14. The method of claim 10 , wherein 12 weeks of said administering is effective to reduce apolipoprotein B in the at least one subject.
15. The method of claim 10 , wherein 12 weeks of said administering is effective to reduce VLDL-C in the at least one subject.
16. The method of claim 10 , wherein the group of subjects has a median fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.
17. A method of reducing triglycerides comprising, identifying a group of subjects having a median triglyceride level of at least 500 mg/dl and orally administering daily to at least one subject in the group a pharmaceutical composition comprising about 4 g of a pharmaceutical composition comprising at least about 90% ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters, by weight of all fatty acids, for a period of 12 weeks to reduce fasting triglycerides in the at least one subject.
18. The method of claim 17 , wherein the group of subjects has a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.
19. The method of claim 17 , wherein the group of subjects has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl, a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl, a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl, or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.
20. The method of claim 17 , wherein 12 weeks of said administering is effective to reduce triglycerides by at least about 30% without increasing LDL-C in the at least one subject.
21. The method of claim 17 , wherein 12 weeks of said administering is effective to reduce apolipoprotein B in the at least one subject.
22. The method of claim 17 , wherein 12 weeks of said administering is effective to reduce VLDL-C in the at least one subject.
23. The method of claim 17 , wherein the group of subjects has a median fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.
24. The method of claim 17 , wherein the composition is present in one or more dosage units.
25. The method of claim 24 , wherein the dosage units are capsules.